Cargando…

Turning the tables on cytomegalovirus: targeting viral Fc receptors by CARs containing mutated CH2–CH3 IgG spacer domains

BACKGROUND: During infection with human cytomegalovirus (HCMV) several viral proteins occur on cell surfaces in high quantity. We thus pursue an HLA-independent approach for immunotherapy of HCMV using chimeric antigen receptors (CARs) and bispecific BiTE(®) antibody constructs. In this context, HCM...

Descripción completa

Detalles Bibliográficos
Autores principales:	Proff, Julia, Brey, Charlotte U., Ensser, Armin, Holter, Wolfgang, Lehner, Manfred
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5804023/ https://www.ncbi.nlm.nih.gov/pubmed/29422056 http://dx.doi.org/10.1186/s12967-018-1394-x

Ejemplares similares

Cytomegalovirus-Infected Cells Resist T Cell Mediated Killing in an HLA-Recognition Independent Manner
por: Proff, Julia, et al.
Publicado: (2016)

Interactions of IgG1 CH2 and CH3 Domains with FcRn
por: Ying, Tianlei, et al.
Publicado: (2014)

A gB/CD3 bispecific BiTE antibody construct for targeting Human Cytomegalovirus-infected cells
por: Brey, Charlotte U., et al.
Publicado: (2018)

In Vitro and In Vivo Comparison of Lymphocytes Transduced with a Human CD16 or with a Chimeric Antigen Receptor Reveals Potential Off-Target Interactions due to the IgG2 CH2-CH3 CAR-Spacer
por: Clémenceau, Béatrice, et al.
Publicado: (2015)

Chimeric antigen receptors (CARs) incorporating mutations in the IgG4 Fc spacer region to eliminate Fc receptor recognition results in improved CAR T cell persistence and anti-tumor efficacy
por: Jonnalagadda, Mahesh, et al.
Publicado: (2013)

Ch-ch-ch-ch-ch-changes
Publicado: (2000)

Ch-ch-ch-ch-Changes
por: Madden, Ken M.
Publicado: (2011)

Conformational Control of Polysilanes: Use of CH(2) Spacers in the Silicon Backbone
por: Wallner, Andreas, et al.
Publicado: (2011)

The binding affinity of human IgG for its high affinity Fc receptor is determined by multiple amino acids in the CH2 domain and is modulated by the hinge region
Publicado: (1991)

An engineered human IgG1 CH2 domain with decreased aggregation and nonspecific binding
por: Cao, Guangcan, et al.
Publicado: (2019)

The differential ability of human IgG1 and IgG4 to activate complement is determined by the COOH-terminal sequence of the CH2 domain
Publicado: (1991)

Human cytomegalovirus antagonizes activation of Fcγ receptors by distinct and synergizing modes of IgG manipulation
por: Kolb, Philipp, et al.
Publicado: (2021)

Mutation of Y407 in the CH3 domain dramatically alters glycosylation and structure of human IgG
por: Rose, Rebecca J., et al.
Publicado: (2013)

Genetic Removal of the CH1 Exon Enables the Production of Heavy Chain-Only IgG in Mice
por: Zhang, Tianyi, et al.
Publicado: (2018)

Stability assessment on a library scale: a rapid method for the evaluation of the commutability and insertion of residues in C-terminal loops of the CH3 domains of IgG1-Fc
por: Hasenhindl, Christoph, et al.
Publicado: (2013)

Corrigendum: Genetic Removal of the CH1 Exon Enables the Production of Heavy Chain-Only IgG in Mice
por: Zhang, Tianyi, et al.
Publicado: (2019)

Specificity of fc receptors for IgG2a, IgG1/IgG2b, and IgE on rat macrophages
Publicado: (1981)

B-lymphocytes activation by the Fc region of IgG
Publicado: (1977)

Fc-Mediated Functions of Porcine IgG Subclasses
por: Paudyal, Basudev, et al.
Publicado: (2022)

CARs—A New Perspective to HCMV Treatment
por: Bednar, Christopher, et al.
Publicado: (2021)

Human IgG/FcγR Interactions Are Modulated by Streptococcal IgG Glycan Hydrolysis
por: Allhorn, Maria, et al.
Publicado: (2008)

Differences in IgG Fc Glycosylation Are Associated with Outcome of Pediatric Meningococcal Sepsis
por: de Haan, Noortje, et al.
Publicado: (2018)

Mouse Antibody of IgM Class is Prone to Non-Enzymatic Cleavage between CH1 and CH2 Domains
por: Klaus, Tomasz, et al.
Publicado: (2018)

The role of Fc–FcγR interactions in IgG-mediated microbial neutralization
por: Bournazos, Stylianos, et al.
Publicado: (2015)

IgG4 antibodies from patients with asymptomatic bancroftian filariasis inhibit the binding of IgG1 and IgG2 to C1q in a Fc-Fc-dependent mechanism
por: Prodjinotho, Ulrich F., et al.
Publicado: (2019)

IgG-Fc glycosylation before and after rituximab treatment in immune thrombocytopenia
por: Schmidt, David E., et al.
Publicado: (2020)

Turning the Tables
Publicado: (1888)

Decreasing hydrophobicity or shielding hydrophobic areas of CH2 attenuates low pH-induced IgG4 aggregation
por: Wu, Qiang, et al.
Publicado: (2023)

ChIP-PED enhances the analysis of ChIP-seq and ChIP-chip data
por: Wu, George, et al.
Publicado: (2013)

FcγR Binding and ADCC Activity of Human IgG Allotypes
por: de Taeye, Steven W., et al.
Publicado: (2020)

Pharmacokinetic Models for FcRn-Mediated IgG Disposition
por: Xiao, Jim J.
Publicado: (2012)

IgG-Fc glycoengineering in non-mammalian expression hosts
por: Loos, Andreas, et al.
Publicado: (2012)

Crystal structure of deglycosylated human IgG4-Fc
por: Davies, Anna M., et al.
Publicado: (2014)

Generation and Characterization of an IgG4 Monomeric Fc Platform
por: Shan, Lu, et al.
Publicado: (2016)

IgG Fc engineering to modulate antibody effector functions
por: Wang, Xinhua, et al.
Publicado: (2017)

IgG and Fcγ Receptors in Intestinal Immunity and Inflammation
por: Castro-Dopico, Tomas, et al.
Publicado: (2019)

The role of IgG Fc receptors in antibody-dependent enhancement
por: Bournazos, Stylianos, et al.
Publicado: (2020)

Impact of Fc N-glycan sialylation on IgG structure
por: Zhang, Zhongqi, et al.
Publicado: (2019)

The therapeutic potential of sialylated Fc domains of human IgG
por: Pleass, Richard J.
Publicado: (2021)

Synthetic nanobodies as tools to distinguish IgG Fc glycoforms
por: Kao, Kevin S., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_85nkp37svjtft2mokotpmagv7f